Onco-Innovations Announces Private Placement

Rhea-AI Summary

Onco-Innovations (OTCQB:ONNVF) announced a non-brokered private placement of up to 2,272,727 Units at $0.88 per Unit to raise gross proceeds of up to $2,000,000. Each Unit includes one common share and one-half warrant, with each whole warrant exercisable to buy one share at $1.10 for 36 months. The company will issue Admin Fee Shares equal to 1.0% of Shares issued in the placement to an arm's-length third party and may pay finders' fees or issue finders' warrants on warrant terms. Closing is subject to regulatory approvals; securities will carry a four-month-plus-one-day hold. Proceeds are intended for general corporate, working capital, R&D and investor relations purposes. Securities are not registered for sale in the United States.

Positive

• Up to $2,000,000 gross proceeds available from the Private Placement
• Warrants exercisable at $1.10 for 36 months, providing potential future capital on exercise

Negative

• Issuance of up to 2,272,727 Units will dilute existing shareholders
• Company will issue Admin Fee Shares equal to 1.0% of placement shares and may pay finders' fees/warrants

Not for distribution to United States wire services or for dissemination in the United States

VANCOUVER, BC / ACCESS Newswire / January 23, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") of up to 2,272,727 units of the Company (the "Units") at a price of $0.88 per Unit, for aggregate gross proceeds of up to $2,000,000. Each Unit shall consist of one common share (each a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"), with each Warrant entitling the holder to purchase one Share at an exercise price of $1.10 for a period of thirty-six (36) months.

The Company also intends to issue Shares equal to 1.0% of the total of Shares issued in the Private Placement (the "Admin Fee Shares") to an arm's-length third party, as an administrative fee for their assistance with the Private Placement.

In connection with the Private Placement, the Company may pay finders' fees and/or issue finders' warrants on the same terms as the Warrants, to eligible parties who have assisted by introducing subscribers to the Private Placement.

Closing of the Private Placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. The Company intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives and for investor relations purposes.

The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:

Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated use of funds and closing date thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be lower than expected, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

What is Onco-Innovations (ONNVF) offering in the January 24, 2026 private placement?

Up to 2,272,727 Units at $0.88 per Unit, each Unit containing one share and one-half warrant, to raise up to $2,000,000.

What are the warrant terms in Onco-Innovations' ONNVF private placement?

Each whole warrant allows purchase of one share at an exercise price of $1.10 and expires after 36 months.

How will Onco-Innovations (ONNVF) use the proceeds from the private placement?

Proceeds are intended for general corporate and working capital purposes, including operational and R&D objectives and investor relations.

Will Onco-Innovations (ONNVF) pay fees to intermediaries for the private placement?

The company may pay finders' fees and/or issue finders' warrants on the same terms as the placement warrants to eligible introducers.

Are the securities from Onco-Innovations' private placement available in the United States?

No. The securities have not been and will not be registered under the U.S. Securities Act and may not be offered or sold in the United States.

When can investors trade shares issued in the Onco-Innovations (ONNVF) private placement?

All securities issued under the placement will be subject to a hold period of four months and one day under applicable securities laws, subject to regulatory approvals.